ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-DLL3/Exatecan Antibody-drug Conjugate IBI3009

Its studies are mostly in Small Cell Lung Carcinoma, led by Innovent Biologics.

Furthest: phase 1, since Sep 22, 20241 company-led study, 1 open or runningNext primary completion: Aug 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Innovent Biologics11 open or runningphase 1since Sep 22, 2024Sep 22, 2024Aug 30, 2027phase 1 · NCT06613009
  • Named in hoffmann la roche’s own pipeline as RG6810 DLL3 ADC (Innovent), phase 1, as of Oct 22, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 22, 2024First study: phase 1 study in Small Cell Lung CarcinomaFirst studyNCT06613009 · 190 planned · Australia, China

Ahead

  1. Aug 30, 2027Primary completion: phase 1 study in Small Cell Lung CarcinomaNCT06613009

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06613009Small Cell Lung Carcinoma · Australia, China1RecruitingAug 30, 2027190

How it is read

Names in the registry

  • “IBI3009”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.